<DOC>
	<DOCNO>NCT00235781</DOCNO>
	<brief_summary>The aim trial compare safety efficacy single dose Thymoglobulin , rabbit derive antithymocyte globulin ( Thymoglobulin , SangStat , Fremont , CA ) standard four dose , four day Thymoglobulin induction regimen time transplantation six month follow-up period . The primary endpoint incidence acute rejection . Secondary endpoint include serious adverse event , evaluation renal function , patient graft survival , incidence infectious complication , incidence post-transplantation lymphoproliferative disorder ( PTLD ) , duration extent lymphocyte depletion immunoassays evidence recipient immune response allograft well duration hospital stay .</brief_summary>
	<brief_title>Single Dose Thymoglobulin Induction Adult Renal Allograft Recipients</brief_title>
	<detailed_description>Induction therapy , use polyclonal monoclonal antibody preparation adjunct immunosuppressive agent initial transplant period , help decrease incidence acute rejection significantly . In 1980 ’ acute rejection occur approximately 50 % renal transplant recipient . In current era transplantation , combination potent induction agent newly available maintenance immunosuppressive agent reduce acute rejection rate le 20 % transplant center . Our center routinely achieve acute rejection rate approximately 5 % use standard induction protocol polyclonal antibody agent Thymoglobulin . Preventing acute rejection significantly decrease requirement re-hospitalization , need diagnostic renal allograft biopsy subsequent exposure high dose corticosteroid immunosuppressive agent . The threat early allograft loss secondary rejection refractory treatment permanent injury shorten graft survival follow treatment severe rejection also circumvent . Polyclonal antibody preparation produce immunize animal human lymphocytes thymocytes . Polyclonal antibody preparation approve treatment acute renal allograft rejection , routinely use induction agent prevention rejection solid organ allograft . Commercially available preparation United States equine/thymocyte derive ( Atgam , Pharmacia &amp; Upjohn , Kalamazoo , MI ) rabbit/thymocyte derive ( Thymoglobulin , Genzyme , Cambridge , MA ) . Rabbit derive preparation think potentially efficacious equine derive product . Studies perform renal transplant center demonstrate Thymoglobulin superior efficacy compare Atgam prevention rejection ( 1 ) . Not acute rejection rate lower , graft survival also well 1 5-years ( 1 ) . [ Hardinger , 2004 # 18 ] . This result attribute part pronounce prolonged lymphopenia induce Thymoglobulin ( 2 ) . The broad specificity polyclonal agent multiple cell signal adhesion molecule provide theoretic advantage compare monoclonal antibody . In addition induce profound prolong lymphopenia complement-dependent lysis opsonization phagocytosis , broad specificity polyclonal antibody agent affect multiple costimulatory adhesion molecule involve cellular antibody mediate immune process . The effect adhesion molecule , cytokine , chemokines platelet may critical note decrease incidence delay renal allograft function associate initiation Thymoglobulin therapy intraoperatively ( 3 ) . Prevention delay graft function may also subsequently decrease incidence acute rejection prolong allograft survival . The use potent induction agent Thymoglobulin also allow delay introduction maintenance immunosuppression calcineurin inhibitor immediate post-transplant setting . The ability delay introduction therapeutic dos calcineurin inhibitor , necessary , also assist decrease incidence delay graft function simplify patient management time period . Thymoglobulin become preferred polyclonal agent use induction renal transplantation . The recent complete yearly data Scientific Registry Transplant Recipients 2003 indicate 70 % renal transplant recipient calendar year receive form induction therapy . Thymoglobulin ( 34 % patient ) commonly administer agent , one two available monoclonal antibody preparation direct interleukin-2 receptor ( IL2-R ) administer approximately 35 % renal transplant recipient ( 4 ) . When Thymoglobulin use treatment acute rejection , total dose 10-12mg/kg often administer course several day ( 5 ) . The optimal dose Thymoglobulin administer induction unclear , although primate model suggest total human equivalent dose approximately 6mg/kg may appropriate ( 6 ) . Most transplant center use Thymoglobulin induction administer total dose 6-10mg/kg , give vary interval ( usually daily every day ) individual dose usually give 1 1.5mg/kg/day approximately six hour . Our standard induction protocol 1.5mg/kg/day total four dos ( total dose 6mg/kg ) . The ability administer Thymoglobulin single , large dose several potential pharmacoeconomic benefit . This administration protocol would simplify post-transplant care hospital allow earlier patient discharge . Cost saving would result short hospital stay decreased administration cost associate few intravenous administration . The administration single , large dose infusion Thymoglobulin use attempt induce “ prope´ ” ( Latin almost ) allograft tolerance ( 7 ) . In study , include 50 renal allograft recipient , single dose infusion Thymoglobulin ( 5mg/kg ) use conjunction mark minimization maintenance immunosuppression . The induction protocol well tolerate , maintenance immunosuppression consist monotherapy tacrolimus . Another study describe administration Thymoglobulin 5mg/kg/day give two separate dos ( 10mg/kg total ) 39 renal allograft recipient ( 8 ) . One dose administer day transplantation subsequent dose post-transplant day number one . No patient study withdrawn secondary adverse event acute rejection rate 6 % patient graft survival 95 % mean follow-up 14.5 month . We previously perform short course Thymoglobulin induction study use initial dose 3mg/kg subsequent dos 1.5mg/kg post-transplant day one two ( 9 ) . This regimen well tolerate result low acute rejection rate 5 % , one year graft survival 95 % early hospital discharge compare previously standard seven day Thymoglobulin induction protocol . Thus , hypothesize single dose Thymoglobulin ( 6mg/kg ) , initiate intraoperatively administer course 24 hour , comparable safety efficacy compare current standard induction protocol four separate dos Thymoglobulin 1.5mg/kg ( total dose 6mg/kg ) . Single dose administration Thymoglobulin provide low rate acute rejection , low rate delay graft function , allow delay introduction calcineurin inhibitor indicate , potentially allow earlier patient discharge consume few resource . If single dose induction protocol demonstrate similar safety efficacy current standard four dose induction protocol , may become standard care . This study may also bridge subsequent dose find study single dose Thymoglobulin administration subsequent comparative study single-dose Thymoglobulin induction agent . 1 . Brennan DC , Flavin K , Lowell JA , et al . A randomized , double-blinded comparison Thymoglobulin versus Atgam induction immunosuppressive therapy adult renal transplant recipient . Transplantation 1999 ; 67 ( 7 ) :1011-1018 . 2 . Hardinger KL , Schnitzler MA , Miller B , et al . Five-year follow thymoglobulin versus ATGAM induction adult renal transplantation . Transplantation 2004 ; 78 ( 1 ) :136-141 . 3 . Goggins WC , Pascual MA , Powelson JA , et al . A prospective , randomize , clinical trial intraoperative versus postoperative Thymoglobulin adult cadaveric renal transplant recipient . Transplantation 2003 ; 76 ( 5 ) :798-802 . 4 . Shapiro R , Young JB , Milford EL , et al . Immunosuppression : evolution practice trend , 1993-2003 . Am J Transplant 2005 ; 5 ( 4 Pt 2 ) :874-886 . 5 . Gaber AO , First MR , Tesi RJ , et al . Results double-blind , randomize , multicenter , phase III clinical trial Thymoglobulin versus Atgam treatment acute graft rejection episodes renal transplantation . Transplantation 1998 ; 66 ( 1 ) :29-37 . 6 . Preville X , Flacher M , LeMauff B , et al . Mechanisms involve antithymocyte globulin immunosuppressive activity nonhuman primate model . Transplantation 2001 ; 71 ( 3 ) :460-468 . 7 . Starzl TE , Murase N , Abu-Elmagd K , et al . Tolerogenic immunosuppression organ transplantation . Lancet 2003 ; 361 ( 9368 ) :1502-1510 . 8 . Uslu A , Nart A , Coker I , et al . Two-day induction thymoglobulin kidney transplantation : risk benefit . Transplant Proc 2004 ; 36 ( 1 ) :76-79 . 9 . Agha IA , Rueda J , Alvarez A , et al . Short course induction immunosuppression thymoglobulin renal transplant recipient . Transplantation 2002 ; 73 ( 3 ) :473-475 .</detailed_description>
	<criteria>1 . Patients 18 year age old 2 . All consent adult renal transplant recipient schedule receive induction therapy ( deceased donor , livingrelated , livingunrelated ) 3 . Females childbearing age must negative pregnancy test perform time admission transplantation 4 . Patient guardian agrees participate study sign inform consent . 5 . No known contraindication administration Thymoglobulin 1 . A known allergy rabbit proteins previous significant intolerance Thymoglobulin administration 2 . Pregnant woman nurse mother 3 . Patients serological evidence infection HIV1 , human Tcell leukemia virus type 1 ( HTLV1 ) , presence serum hepatitis B surface antigen ( HBsAg ) 4 . Recipients human leukocyte antigen ( HLA ) identical living donor renal allograft ( 2haplotype match ) 5 . Recipients simultaneous multiple organ transplantation 6 . Recipients preexist , nonrenal , solid organ transplant 7 . Recipients ≥2 previous renal allograft 8 . Patients history malignancy evidence recurrence within 2 year ( except adequately treat localize squamous basal cell carcinoma skin ) . 9 . Any patient , opinion investigator , significant medical psychosocial problem preclude study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2006</verification_date>
	<keyword>Kidney Transplantation</keyword>
	<keyword>Antilymphocyte Serum</keyword>
	<keyword>Induction</keyword>
	<keyword>Graft Rejection</keyword>
</DOC>